Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population

pharmafile | August 5, 2019 | News story | Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma 

German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) followed by AstraZeneca’s Tagrisso (osimertinib) in the treatment of epidermal growth factor receptor mutation-positive (EGFRM+) non-small cell lung cancer (NSCLC) in patients with acquired T790M mutations.

Previously released data from the study detailed overall survival (OS) rates after two years and after 30 months, but the incorporation of electronic health record data from a sub-set of US patients identified the median OS benefit for the therapy to be 41.3 months after a median follow-up of 30.3 months, with a two-year OS rate of 80%.

The additional data also determined that patients whose tumours were Del19-positive were more likely to reap even greater benefit, with this population displaying a median OS of 45.7 months and two-year OS rate of 82%.

“As many patients with this type of lung cancer eventually acquire resistance to EGFR TKIs, it’s important to consider the order of these therapies to provide patients with as many future treatment options as possible,” remarked Maximilian J Hochmair, a coordinating investigator in the study and a Medical Pulmonologist at the Department of Internal Medicine and Pneumology, Krankenhaus Nord, Klinik Floridsdorf. “The updated GioTag study findings provide supportive evidence that afatinib followed by osimertinib is a viable treatment sequence option for patients with EGFR M+ NSCLC.”

Dr Victoria Zazulina, Corporate Vice President and Global Head of Oncology, Medicine, at Boehringer Ingelheim, also commented: “The continued clinical development of new EGFR TKIs provides additional treatment options for patients with EGFRM+ NSCLC, and raises questions about their optimal sequence. Given that, as yet, no established targeted treatment options are available following failure of osimertinib, there is an argument for reserving osimertinib for second-line use after second-generation EGFR TKIs. Real-world data from the GioTag study supports the argument for sequential use of afatinib and osimertinib for patients with EGFR M+ NSCLC who are Del19-positive.”

Matt Fellows

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to …

Latest content